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Introduction {#sec1}
============

Hematopoietic development and differentiation are regulated through a hierarchical network of DNA-sequence-specific transcription factors. Genetic alterations affecting such regulators impair the balance of interactions within their corresponding transcriptional network, leading to a disturbance of differentiation and enhanced self-renewal. Acute myeloid leukemia (AML) is a heterogeneous disease marked by proliferation of neoplastic cells with impaired myeloid differentiation. The t(8;21) translocation, accounting for approximately 10% of all AML, fuses the DNA binding domain of the hematopoietic master regulator RUNX1 to almost the entire ETO protein ([@bib37]). The resulting RUNX1-ETO fusion protein phenotypically functions as a dominant-negative version of RUNX1 by blocking hematopoietic development both *in vivo* and *in vitro* ([@bib52], [@bib68]). It recruits histone deacetylase complexes to RUNX1 binding sites through its ETO moiety, resulting in repression of genes that regulate hematopoietic differentiation ([@bib31], [@bib52]). Experiments depleting RUNX1-ETO in established AML cells have shown that it is required to maintain leukemic growth ([@bib46]) but have also demonstrated that RUNX1-ETO-regulated gene expression is complex, with multiple genes being up- and downregulated after knockdown ([@bib47], [@bib48]), indicating that the entire transcriptional network of such cells is rewired in the presence of the fusion protein.

The t(8;21) translocation can occur early during development and has been detected *in utero* ([@bib67]), indicating that its presence does not interfere with general hematopoietic differentiation in human embryos after formation of progenitor cells. Moreover, t(8;21) patients in remission can harbor pre-leukemic stem cells carrying the translocation but lacking secondary mutations, which may serve as a reservoir for relapse ([@bib36], [@bib59]). These findings agree with the findings of experiments modeling the disease in mice, demonstrating that RUNX1-ETO alone is not sufficient to cause AML ([@bib19], [@bib69]). Given that leukemia development requires the acquisition of multiple genetic aberrations, the study of primary cells from patient leukemic samples does not allow easy discrimination of the impact of RUNX1-ETO alone on the gene regulatory network of normal blood progenitor cells. Several studies examined the development of AML using inducible RUNX1-ETO expression in mice or constitutive expression in human cells *in vitro*. However,AML development was slow ([@bib12]), the proliferation of cells in the culture dish implied the requirement for a selection step ([@bib32], [@bib38], [@bib39]), RUNX1-ETO was induced at higher levels than those seen in patients ([@bib38], [@bib39]), and assays were performed in established cell lines harboring additional mutations ([@bib33], [@bib46], [@bib47]) or in *in vitro*-differentiated hematopoietic cells resembling yolk-sac-like progenitors that are unlikely to represent the proper target cell types ([@bib32], [@bib64]). These caveats hinder the understanding of the earliest, unperturbed chromatin reprogramming events occurring in a human setting after RUNX1-ETO induction. To circumvent these limitations, we genetically altered human pluripotent stem cells to activate *RUNX1-ETO* in response to doxycycline (Dox) and used an *in vitro* system of hematopoietic differentiation that biases cultures toward definitive multipotent hematopoietic progenitor cells ([@bib41]).

Our experiments showed that high levels of RUNX1-ETO had a detrimental effect on hematopoiesis. However, levels of *RUNX1-ETO* expression that matched those of endogenous *RUNX1* in immature clonogenic blood progenitors were compatible with cellular survival. Within 24 h of *RUNX1-ETO* induction, cells became quiescent and downregulated hematopoietic differentiation, cell-cycle, and DNA repair genes but upregulated mitogen-activated protein kinase (MAPK) and vascular endothelial growth factor (VEGF) signaling pathway genes. In contrast to uninduced cells, these cells could survive for months *in vitro* without proliferating. Strikingly, following the removal of Dox and the cessation of *RUNX1-ETO*, transcription these immature, quiescent *RUNX1-ETO*-expressing cells revealed an enhanced clonogenic capacity and regained the ability to proliferate and differentiate. Chromatin immunoprecipitation (ChIP) and chromatin accessibility assays showed that RUNX1-ETO binding led to widespread loss of chromatin accessibility at RUNX1 binding sites and substantially altered the RUNX1-controlled transcriptional program. Single-cell RNA sequencing (scRNA-seq) experiments demonstrated that RUNX1-ETO induction exerted its main impact on an early myeloid precursor population, by downregulating the myeloid master regulator PU.1, but had little effect at later stages or different lineages. Our study sheds light on the earliest events occurring after RUNX1-ETO expression in a human primary cell setting and demonstrates a dissociation between block in differentiation and cell proliferation, considered the two hallmarks of leukemia.

Results {#sec2}
=======

Expression of *RUNX1-ETO* Leads to Reversible Differentiation and Growth Arrest of Human Early Hematopoietic Progenitor Cells {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------

To analyze the effects of RUNX1-ETO induction in defined cell types, we generated inducible RUNX1-ETO human embryonic stem cell (ESC) lines. The parental line used was a previously generated human H9 ESC dual reporter cell line (denoted SOX17^mCHERRY/w^RUNX1C^GFP/w^) carrying an *mCHERRY* gene in the *SOX17* locus, marking arterial endothelium ([@bib13]), and a *GFP* gene in the *RUNX1* locus, resulting in expression of GFP from the distal promoter (*RUNX1C*) and hence marking hematopoietic stem cells (HSCs) and progenitor cells ([@bib41]; [Figure S1](#mmc1){ref-type="supplementary-material"}A). *RUNX1C* is the dominant *RUNX1* isoform in fetal liver blood progenitors ([@bib60]). In contrast to *RUNX1B*, *RUNX1C* expression is restricted to hematopoietic cells and defines the subset of CD34+ cells with clonogenic and bone marrow homing activity ([@bib41]). This strategy allowed us to track the progression of *in vitro* cell differentiation ([Figures 1](#fig1){ref-type="fig"}A and 1B; [Figure S1](#mmc1){ref-type="supplementary-material"}B), thus facilitating the distinction between endothelial and hematopoietic cells. It also allowed us to monitor the endothelial-to-hematopoietic transition (EHT), the process by which hematopoietic progenitor cells form and detach from the endothelium, which is accompanied by a switch in *RUNX1* promoter usage ([@bib3], [@bib5], [@bib15], [@bib22], [@bib25], [@bib26], [@bib42]). We derived definitive hematopoietic progenitors from human ESC lines using a protocol that included SB431542 and CHIR (an ACTIVIN inhibitor and a WNT agonist, respectively) from day 2--4 to pattern cells toward an intra-embryonic, definitive *HOXA+* fate ([@bib41]; [Figure 1](#fig1){ref-type="fig"}A). By differentiating the dual reporter cell line using this protocol, we were able to visualize RUNX1C+ progenitors emerging from SOX17+ hemogenic endothelium, forming cell clusters that resembled progenitor formation within the 5^th^ week of human embryonic development in the aorta-gonad-mesonephros (AGM) ([@bib41]; [Figure 1](#fig1){ref-type="fig"}B; [Figure S1](#mmc1){ref-type="supplementary-material"}B).Figure 1Expression of *RUNX1-ETO* Leads to a Differentiation Arrest of Human Early Hematopoietic Progenitor Cells(A) Protocol for *in vitro* human definitive hematopoietic differentiation as spin embryoid bodies (EBs). Developmental stages, time course, and growth factors used are indicated. Epi-fluorescence images (human embryonic stem cells \[hESCs\], days 2 and 6) and confocal images (days 10--28) representative of each stage are shown. A pulse of SB431542 and CHIR (red) was included from days 2--4. hESCs are shown \~50% confluency on a feeder layer. EBs (days 2 and 6) appear as opaque round structures and are surrounded by adherent stroma, endothelium, and blood cells from day 10. Fluorescence and bright-field channels are merged in images corresponding to days 10, 13, and 28. Scale bar: 100 μm. SOX17 (mCHERRY, red) expression marks vascular structures, and RUNX1C (GFP, green) marks hematopoietic progenitors.(B) Confocal image of a differentiation culture at day 17 showing RUNX1C+ progenitors being generated from SOX17+ vascular structures of endothelial cells, resembling embryonic AGM hematopoiesis. SOX17 (CHERRY, red), RUNX1C (GFP, green). The arrow points to groups of progenitor cells resembling the embryonic intra-aortic hematopoietic cell clusters. Scale bar: 100 μm.(C) Schematic representation of the transgene targeting the AAVS1 locus. Knockin was performed via transcription activator-like effector nuclease (TALEN)-mediated homologous recombination into the AAVS1 locus of the SOX17^mCHERRY/w^ RUNX1C^GFP/w^ hESC line H9. The integrated sequence includes an HA-tagged *RUNX1-ETO* cDNA under control of a tetracycline-inducible expression system (TRE-3G), the reverse tetracycline activator (rtTA) controlled by a chicken β-actin promoter (CAG), and a puromycin resistance gene with an upstream T2A sequence to link its expression to the AAVS1 gene.(D) Experimental strategy for the evaluation of RUNX1-ETO induced by Dox (0, 3, 5, or 10 ng/mL). Cultures were treated with Dox at different time points once blood progenitors were had been formed (days 21--27). The non-adherent hematopoietic cell fraction was harvested 7 days after induction and used for flow cytometry analysis and CFU and replating assays.(E) Confocal images of hematopoietic cultures at day 17, showing the disruptive effects on vasculogenesis and blood formation of RUNX1-ETO induction before the EHT, which occurs around day 12 in our cultures. Images are representative of uninduced and induced cultures at day 10 (5 ng/mL Dox for 7 days). SOX17 (CHERRY) and RUNX1C (GFP). Scale bar: 100 μm.(F) Confocal images of hematopoietic cultures at day 28 showing the effect of RUNX1-ETO on formation of blood progenitors. *RUNX1-ETO* expression at an equivalent level to that of endogenous RUNX1 (5 ng/mL Dox) allows vasculogenesis and blood formation to occur, whereas higher *RUNX1-ETO* expression levels (10 ng/mL Dox) result in the formation of abnormal vascular structures and reduced blood formation. Images are representative of uninduced and induced cultures at day 21 with 5 or 10 ng/mL Dox for 7 days. SOX17 (CHERRY) and RUNX1C (GFP). Scale bar: 100 μm.(G) *RUNX1-ETO*-expressing cultures retain markers of immature myeloid progenitors. Flow cytometry analysis of the floating fraction of day 34 hematopoietic progenitors upon 7-day RUNX1-ETO induction (3, 5, or 10 ng/mL Dox at day 27). Results are representative of three biological replicates with comparable results with induction at different time points after the EHT. Accumulated precursor cells are highlighted pink.

We next generated cell lines carrying an N-terminal hemagglutinin (HA)-tagged *RUNX1-ETO* cDNA, expressed in a Dox-inducible manner and targeted to the safe harbor AAVS1 locus ([Figure 1](#fig1){ref-type="fig"}C). Induction of HA-*RUNX1-ETO* occurred homogeneously within the cell population ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). We first determined the Dox concentration required to induce *RUNX1-ETO* expression in hematopoietic progenitors to levels that mimicked the balanced ratio of *RUNX1-ETO*:*RUNX1* expression observed in AML patients ([Figure S1](#mmc1){ref-type="supplementary-material"}E), suggesting 3--5 ng/mL Dox as the most appropriate concentrations. Induction with 5 ng/mL Dox yielded RUNX1-ETO protein levels equivalent to those of endogenous RUNX1 ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Higher Dox concentrations (100--500 ng/mL) that further increased *RUNX1-ETO* levels abrogated blood formation (data not shown). To examine the dose responsiveness of hematopoiesis to *RUNX1-ETO* expression, we induced differentiating cells with 3, 5, or 10 ng/mL Dox for 7 days ([Figure 1](#fig1){ref-type="fig"}D). Dox induction before the EHT resulted in severe disorganization of the SOX17+ vasculature and an overall reduction of blood cells that also appeared phenotypically abnormal ([Figure 1](#fig1){ref-type="fig"}E; [Figure S1](#mmc1){ref-type="supplementary-material"}G). Abnormal progenitors either lacked *RUNX1C* (GFP) expression, failed to downregulate *SOX17* (CHERRY+), or co-expressed *SOX17* and *RUNX1C* (CHERRY+ and GFP+). However, induction after the EHT allowed the generation of phenotypically normal blood cells, with only 10 ng/mL Dox reducing blood cell numbers ([Figure 1](#fig1){ref-type="fig"}G). Expression of *RUNX1-ETO* affected the nature of the hematopoietic cells present in our cultures, causing a Dox-dependent decrease of RUNX1C+ and CD16+ myeloid cells and an increase of CD34+CD38−CD90+ populations resembling immature blood progenitors ([Figure 1](#fig1){ref-type="fig"}G).

RUNX1-ETO induction reduced colony-forming ability in a dose-dependent manner in colony-forming unit (CFU) assays in Dox-containing methylcellulose medium ([Figure 2](#fig2){ref-type="fig"}A; [Figure S1](#mmc1){ref-type="supplementary-material"}H, left panel). However, CFU activity was restored once Dox was removed from the methylcellulose ([Figure 2](#fig2){ref-type="fig"}A; [Figure S1](#mmc1){ref-type="supplementary-material"}H, right panel), indicating reversibility of the RUNX1-ETO-dependent proliferation block. The presence or absence of Dox did not affect colony size or morphology, suggesting that the clonogenic cells differentiated normally following removal of Dox (data not shown). Moreover, long-term culture of hematopoietic cells in the presence of low levels of RUNX1-ETO (3--5 ng/mL Dox) prolonged cell survival without resulting in cell proliferation ([Figures 2](#fig2){ref-type="fig"}B and 2C; [Figures S1](#mmc1){ref-type="supplementary-material"}I and S1J). In addition, the presence of RUNX1-ETO caused a profound decrease in DNA-synthesis activity because of an arrest in the G1 phase of the cell cycle, as measured by bromodeoxyuridine (BrdU) incorporation, without an increase in cell death ([Figure S1](#mmc1){ref-type="supplementary-material"}K).Figure 2RUNX1-ETO Induction Leads to Increased Survival and a Reversible Growth Arrest(A) RUNX1-ETO induction causes a reversible block in colony-forming ability. Top: diagram depicting the experimental strategy. EB cultures were treated with 3, 5, or 10 ng/mL Dox for 7 days, and suspension cells were subsequently plated in methylcellulose for CFU assays in the presence or the absence of Dox. Below: CFU assay of day 31 progenitors from treated EB cultures (at day 24 for 7 days), plated in methylcellulose in the presence (light gray) or absence (dark gray) of Dox. Data are from three independent biologic replicates using two clones. CFU assays were conducted in triplicate, with 3,000 cells plated per well. Error bars represent the standard error of the mean (SEM). Gray asterisk: multiple t test, statistical significance determined using the Holm-Sidak method, with alpha = 0.05. Each row was analyzed individually, without assuming a consistent SD. Black asterisk: two-way ANOVA, statistical significance determined using Dunnett's multiple comparison test.(B) Induction of RUNX1-ETO at low levels (3 and 5 ng/mL Dox) enhances the survival of a subset of progenitor cells compared with uninduced cells, without increasing proliferative capacity. Left: schematic of the replating assays. EB cultures were treated at different stages of hematopoietic differentiation with 0, 3, 5, or 10 ng/mL Dox for 7 days. Floating progenitors were harvested and plated on Matrigel-coated wells at 2 × 10^5^ cells/well in the corresponding Dox concentration and were serially passaged each week. Right: cell count of live cells × 10^5^ during replating assays of hematopoietic progenitors from day 29 cultures previously treated with Dox for 7 days (from day 22), showing one representative of three biological replicates. Cell growth was measured at the indicated times.(C) RUNX1-ETO expressed at low levels allows survival of cells until day 87. Bright-field images of hematopoietic progenitors from replating assays at day 87 of differentiation that are uninduced (left) or treated with 3 ng/mL Dox from day 22 onward (right). Images are taken using the same magnification.

In summary, our experiments show that the expression of balanced levels of *RUNX1-ETO* in developing human blood progenitor cells leads to a reversible block in differentiation with growth arrest and prolongation of cell survival.

RUNX1-ETO Induction Leads to Cell-Type and Dose-Dependent Changes in Gene Expression {#sec2.2}
------------------------------------------------------------------------------------

We previously demonstrated that during mouse *in vitro* hematopoietic specification, RUNX1-ETO reshapes the gene regulatory network in a developmental stage-specific manner and that the outcome depends on the cell type in which the oncogenic event occurs ([@bib52]). To examine the molecular basis of this finding in human cells, we examined genes induced by RUNX1-ETO in two progenitor cell populations (SOX17−CD45+CD34+RUNX1C+^(GFP+)^ and SOX17−CD45+CD34+RUNX1C−^(GFP−)^), isolated from day 22 differentiating cultures, with or without prior induction of RUNX1-ETO with 24 h of Dox treatment ([Figure S2](#mmc1){ref-type="supplementary-material"}A, [Data S1](#mmc2){ref-type="supplementary-material"}). Both populations were composed of CD34+CD45+ progenitors, but the molecular distinction between RUNX1C+ and RUNX1C− populations under uninduced conditions was not known. Analysis of differential gene expression between uninduced RUNX1C+ and RUNX1C− cells showed more than 1,100 differentially expressed genes, demonstrating an intrinsically different nature of the two cell populations ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Expression levels of *RUNX1* and *SPI1* were similar in both populations, but RUNX1C− cells expressed high levels of monocyte-specific genes such as *IRF8*, *CSF1R*, and *CD14*, indicating the presence of maturing myelomonocytic cells ([Data S2](#mmc3){ref-type="supplementary-material"}). RUNX1C+ cells expressed higher levels of *MYB*, *GATA2*, and *GFI1*, as well as the erythroid regulators *GATA1* and *KLF1*. After induction of RUNX1-ETO with 5 ng/mL Dox, both RUNX1C− and RUNX1C+ cell populations up- and downregulated similar numbers of genes ([Figure S2](#mmc1){ref-type="supplementary-material"}C). However, the actual RUNX1-ETO-responsive gene expression program was different ([Figure 3](#fig3){ref-type="fig"}A; [Data S3](#mmc4){ref-type="supplementary-material"}). In accordance, up- and downregulated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in gene sets responding to 5 or 10 ng/mL Dox induction differed as well ([Figure 3](#fig3){ref-type="fig"}B; [Data S4](#mmc5){ref-type="supplementary-material"}). RUNX1C+ cells downregulated cell-cycle and DNA replication genes (such as *BRCA1*, *BUB1B*, and *RNASEH2B*) and upregulated a large number of signaling genes (such as *MAPK3* and *JUN*), whereas RUNX1C− cells downregulated genes belonging to hematopoietic lineage pathways (such as *CEBPA*, *IL4*, and *KIT*) and upregulated only a subset of the genes upregulated in the RUNX1C+ population. In addition, upon treatment with 5 ng/mL Dox, RUNX1C+ cells showed downregulation of genes related to both the G2/M and S phases of the cell cycle ([Figure 3](#fig3){ref-type="fig"}C, right panels), agreeing with the observed cell-cycle arrest upon RUNX1-ETO induction ([Figure S1](#mmc1){ref-type="supplementary-material"}J). In contrast, RUNX1C− cells did not downregulate S-phase genes upon induction, suggesting that these cells were still able to replicate ([Figure 3](#fig3){ref-type="fig"}C, left panels). The gene expression response to RUNX1-ETO induction in RUNX1C+ cells was highly dose dependent ([Figure 3](#fig3){ref-type="fig"}D; [Figure S2](#mmc1){ref-type="supplementary-material"}D). Furthermore, RUNX1-ETO induction yielded highly heterogeneous changes in gene expression, with distinct subsets of genes responding differently to the oncogene dosage ([Figure S2](#mmc1){ref-type="supplementary-material"}E). For example, expression of the stem cell regulator *GATA2* and the *WT1* gene decreased, along with cell-cycle genes (*BUB1* and *CHEK2*) and the growth factor receptor gene *KIT* ([Figure 3](#fig3){ref-type="fig"}E). In contrast, genes involved in signaling pathways (*MAPK3*) and immediate-early response genes (*FOS* and *JUN*) were upregulated ([Figure 3](#fig3){ref-type="fig"}E). These gene expression data were concordant with the observed cell-cycle arrest and demonstrate that RUNX1-ETO affects distinct cell types differently, suggesting that RUNX1-ETO induction in the appropriate cell type is crucial for understanding how it reprograms the epigenome of myeloid cells.Figure 3RUNX1-ETO Induction Leads to Cell-Type and Dose-Dependent Changes in Gene Expression(A) Clustering of gene expression data for sorted populations of RUNX1C− and RUNX1C+ (CD45+CD34+) cells, both wild-type and after 24 h of RUNX1-ETO induction using 5 ng/mL Dox. The figure includes all genes that showed up-/downregulation after RUNX1-ETO induction in either the RUNX1C+ or the RUNX1C− cell populations.(B) Heatmap after KEGG pathway analysis depicting clustering of differentially expressed genes associated with KEGG terms upon RUNX1-ETO induction (5 and 10 ng/mL Dox) in sorted populations of both RUNX1C− and RUNX1C+ cells. Red intensity reflects the enrichment significance of the terms in −log10 (q value).(C) Gene set enrichment analysis (GSEA) correlating expression of genes differentially regulated during the cell cycle (G2/M in top panels and S phase in bottom panels) between induced (5 ng/mL Dox for 24 h) and uninduced conditions in both RUNX1C+ and RUNX1C− cell populations. ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.(D) Bar graph depicting differentially expressed genes between uninduced and Dox-treated (3, 5, and 10 ng/mL Dox) sorted populations of CD45+CD34+RUNX1C+ cells.(E) Examples of individual genes differentially regulated in CD34+RUNX1C+ progenitors in response to RUNX1-ETO induction (3, 5, and 10 ng/mL Dox) for 24 h. n = 3. Each colored dot represents a distinct biological replicate.

RUNX1-ETO Induction Causes Extensive Global Chromatin Reorganization and Disrupts the Binding of RUNX1 at Distal Elements {#sec2.3}
-------------------------------------------------------------------------------------------------------------------------

To understand the RUNX1-ETO-mediated chromatin reprogramming and changes in transcription factor binding in RUNX1C+ cells, we next analyzed open chromatin regions, using the assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq), and protein binding, by performing ChIP experiments ([Figure 4](#fig4){ref-type="fig"}A, [Data S1](#mmc2){ref-type="supplementary-material"}). Induction of RUNX1-ETO shifted the accessible chromatin landscape ([Figure 4](#fig4){ref-type="fig"}B, ATAC-seq); an example for this is the *SPI1* (PU.1) locus that is shown in [Figure 4](#fig4){ref-type="fig"}C. A large number of accessible sites were lost (5,419) and gained (4,112) within 24 h of Dox induction. Lost sites were associated with downregulated gene expression ([Figure 4](#fig4){ref-type="fig"}B, gene expression) and were enriched in binding motifs for important members of hematopoietic transcription factor families, such as PU.1 (but not ETS), as well as GATA, RUNX, and C/EBP family members ([Figures 4](#fig4){ref-type="fig"}B, motif density plots, and [4](#fig4){ref-type="fig"}D). These results were confirmed by chromatin immunoprecipitation sequencing (ChIP-seq) experiments showing loss of RUNX1 binding across all RUNX1-ETO bound sites, as well as a reduction of the active histone marks histone H3 lysine 27 acetylation (H3K27ac) and histone H3 lysine 4 trimethylation (H3K4me3) ([Figures 4](#fig4){ref-type="fig"}B and 4E). These losses were most pronounced on distal elements ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D), whereas promoters were less affected ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). RUNX1-ETO has been shown to associate with several transcription factors, forming a complex containing LMO2, LDB1, and E-Box binding factors, such as LYL1 and ETS family members ERG/FLI1, all of which were shown to be important for chromatin binding and leukemogenesis ([@bib33], [@bib62]). To test how the binding of these factors responded to RUNX1-ETO induction, we measured their binding to both promoter and distal regulatory regions in the presence or absence of RUNX1-ETO using ChIP ([Figures 4](#fig4){ref-type="fig"}B and 4C; [Figures S3](#mmc1){ref-type="supplementary-material"}A and S3C). The binding of RUNX1-ETO was accompanied by an increase in LMO2 binding, whereas the binding of LDB1 appeared to follow the loss of RUNX1. This result is in concordance with LDB1 and RUNX1-ETO knockdown experiments that showed that the reduction of LDB1 binding did not influence the binding of RUNX1-ETO but followed the *de novo* binding of RUNX1 and the establishment of new *cis*-element interactions after RUNX1-ETO depletion ([@bib48]). Loss of RUNX1 binding at specific sites was directly correlated to RUNX1-ETO expression levels ([Figure 5](#fig5){ref-type="fig"}A), with some genomic sites presenting total abrogation of RUNX1 binding upon induction of RUNX1-ETO with 10 ng/mL Dox, as exemplified in the *RASSF5* locus ([Figure 5](#fig5){ref-type="fig"}B), thus demonstrating that the two factors are in direct competition. This idea is supported by most genes that were bound by both factors showing loss of RUNX1 binding after RUNX1-ETO induction ([Figure S3](#mmc1){ref-type="supplementary-material"}E, circles intersection, purple). Around 40% of both upregulated and downregulated genes upon induction were RUNX1-ETO target genes ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Moreover, most differentially expressed RUNX1 targets that lost RUNX1 binding upon induction were RUNX1-ETO target genes, as well ([Data S5](#mmc6){ref-type="supplementary-material"}), with a smaller proportion of non-targets ([Figure S3](#mmc1){ref-type="supplementary-material"}F, light colors). Altogether, our data demonstrate that induction of RUNX1-ETO strongly interferes with the RUNX1-driven gene expression program, mostly by direct competition but also by indirect means.Figure 4RUNX1-ETO Induction Causes Extensive Global Chromatin Reorganization and Blocks the Binding of RUNX1(A) Sorting strategy and downstream analyses after 24-h induction of RUNX1-ETO with 5 ng/mL Dox.(B) Heatmaps depicting accessible chromatin regions ranked by the fold difference between 0 and 5 ng/mL Dox RUNX1C+-treated samples. ATAC-seq peaks were considered sample specific when displaying a greater than 2-fold enrichment compared with the other sample. Sample-specific sites and number of peaks are indicated alongside: red, 5-Dox specific; blue, 0-Dox specific; gray, shared peaks. ChIP-seq enrichment for RUNX1, HA-RUNX1-ETO, LMO2, LDB1, H3K27ac, and H3K4me3 in each sample; motif density plots; and gene expression at these sites are ranked along the same coordinates as the ATAC-seq peaks.(C) Genome browser screenshot at the *SPI1* gene locus depicting RUNX1, HA-RUNX1-ETO, LMO2, LDB1, H3K27ac, and H3K4me3 ChIP-seq and ATAC-seq tracks in uninduced and induced (5 ng/mL Dox for 24 h) samples.(D) Motif enrichment analysis in the 0- and 5-Dox-specific peaks.(E) Average profiles for RUNX1 and RUNX1-ETO ChIP-seq data centered on RUNX1 binding peaks (±1,000 bp from peak center) in the 0- and 5-Dox-specific peaks.Figure 5Analysis of the Interplay between RUNX1 and RUNX1-ETO(A) Average profiles for RUNX1 ChIP-seq tag counts centered on all RUNX1 binding peaks (±1,000 bp from peak center) in the 0, 5, and 10 ng/mL Dox-treated samples.(B) Genome browser screenshot at the *RASSF5* gene locus depicting RUNX1, HA-RUNX1-ETO, and H3K27ac ChIP-seq and ATAC-seq tracks for the indicated samples.(C) Comparison of chromatin accessibility in RUNX1C+ cells (0- and 5-Dox-treated samples) to myeloid progenitor cell types from [@bib14]. Heatmaps show ATAC-seq tag counts ranked by fold difference between 0- and 5-Dox-treated RUNX1C+ samples. ATAC-seq tag counts from distinct myeloid progenitor cell types ([@bib14]) are ranked along the same coordinates as the 0-Dox ATAC-seq peaks. Color intensity reflects tag counts per million, with light blue representing closed chromatin.(D) RUNX1-ETO-induced hESC-derived progenitors share a t(8;21) AML-specific gene expression profile with t(8;21) AML patients. GSEA correlating upregulated (left panel) and downregulated (right panel) RUNX1-ETO target genes between CD45+CD34+RUNX1C+ cells following 24-h RUNX1-ETO induction (5 ng/mL Dox) and the gene expression profile of the RUNX1-ETO targets in t(8;21) patients.

Human ESC-derived multipotent progenitor cells show a transcriptome pattern similar to those of the first pre-HSCs developing from the human AGM ([@bib41]). However, changes in the chromatin structure often precede the onset of transcription ([@bib8]). We therefore wished to determine to what extent the chromatin landscape in our human ESC-derived progenitors resembled that of normal blood stem and progenitor cells. To this end, we compared our ATAC-seq data derived from uninduced and induced cells to those generated from highly purified human hematopoietic precursor populations, as well as monocytic cells ([@bib14]; [Figure 5](#fig5){ref-type="fig"}C). This analysis shows a strong resemblance of the overall ATAC-seq pattern of human ESC-derived RUNX1C+ progenitors to HSC and multi-potent progenitor (MPP) populations, but not to monocytes. RUNX1-ETO induction shifted this pattern, resulting in loss of open chromatin regions specific for early progenitors and appearance of new accessible sites. In human ESC-derived progenitors, RUNX1-ETO induction deregulated a set of genes similar to that found in t(8;21) AML patients when compared with normal CD34+ stem/progenitor cells ([Figure 5](#fig5){ref-type="fig"}D). This result argues that the initial RUNX1-ETO mutation accounts for a large portion of the altered transcriptional network in leukemia patient samples.

*RUNX1-ETO* Acts on Early Myeloid Cells {#sec2.4}
---------------------------------------

To identify the cells most responsive to RUNX1-ETO induction, we performed scRNA-seq experiments, comparing purified CD45+CD34+RUNX1C+ cells with or without 24-h treatment with 5 ng/mL Dox, assigning cell populations based on expression of known lineage marker genes ([Figure 6](#fig6){ref-type="fig"}A; [Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C; [Data S6](#mmc7){ref-type="supplementary-material"}). The clustering analysis in [Figure 6](#fig6){ref-type="fig"}B shows that the uninduced population consisted of early erythroid precursors, eosinophils, together with maturing erythroid and myeloid cells, and a population of less differentiated cells resembling stem and different types of myeloid progenitor cells, as described by [@bib16]; [Figure 6](#fig6){ref-type="fig"}B, left panel). Overnight induction of RUNX1-ETO led to the emergence of an enriched population ([Figure 6](#fig6){ref-type="fig"}B, right panel, green; [Figure S4](#mmc1){ref-type="supplementary-material"}D), herein referred as the 5-Dox-enriched population. Analysis of cell-cycle-regulated genes within this population showed a strong arrest in the G1 phase of the cell cycle ([Figure 6](#fig6){ref-type="fig"}C). Some degree of cell-cycle arrest was also observed in the stem/progenitor, eosinophil, and guanosine monophosphate (GMP)-like populations (orange/purple/dark blue), but not in the erythroid populations (pink/red). A similar result was seen when we measured the number of genes responding to induction ([Figure S4](#mmc1){ref-type="supplementary-material"}E), with the 5-Dox-enriched population (green) presenting the highest number of changing genes, followed by the eosinophil progenitor population (orange) and lastly the erythroid lineage cells (pink and red), which showed only a few responsive genes. We next projected the expression of important hematopoietic regulator genes on the different cell clusters ([Figure 6](#fig6){ref-type="fig"}D). This analysis demonstrated again the differential response to RUNX1-ETO induction between the cell clusters. The quantification of expression of individual genes ([Figure S5](#mmc1){ref-type="supplementary-material"}) showed that the most pronounced response was the loss of *SPI1* (PU.1) expression in the 5-Dox-enriched population, as well as strong upregulation of expression of the *SOX4* transcription factor gene. We also observed a reduction of *GATA2*, *CEBPA*, and *GFI1B* expression. Cells in the 5-Dox-enriched population expressed the chemokine gene *CCL5*, which has roles in proliferation, metastasis, and creating an immunosuppressive environment. As shown earlier, transcription factors relevant for erythroid development and erythroid lineage genes were largely unaffected, as were other genes such as *MEIS1*. Gene expression and KEGG pathway analysis of up- and downregulated genes in the 5-Dox-enriched population are consistent with the results obtained from the bulk RNA-seq data ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B; [Data S7](#mmc8){ref-type="supplementary-material"}). These results show that single-cell analysis of RUNX1-ETO transcriptional dysregulation yielded results similar to the differential gene expression observed in the bulk progenitor population upon 5 ng/mL Dox treatment, confirming the RUNX1-ETO-dependent downregulation of cell cycle, replication, and interestingly, spliceosome and ribosomal genes.Figure 6Induction of RUNX1-ETO in the CD45+CD34+RUNX1C+ Population Results in the Emergence of a New Cell Population(A) Diagram of the sorting strategy for scRNA-seq performed following 24-h induction of RUNX1-ETO (5 ng/mL Dox at day 21).(B) Two-dimensional t-distributed stochastic neighbor embedding (t-SNE) maps displaying 3,321 (left) and 3,814 (right) sorted populations of CD45+CD34+RUNX1C+ single cells following 0 and 5 ng/mL Dox treatment, respectively. Colors represent the different clusters identified after RaceID analysis.(C) Pie charts displaying the proportion of cells in each cell-cycle phase (G1, G2-M, and S) within each cell cluster as identified by expression of cell-cycle-regulated genes, such as histone genes.(D) Expression of individual marker genes projected on the t-SNE maps of both untreated (0 Dox) and treated (5 Dox; 5 ng/mL for 24 h) scRNA populations. Color intensity represents number of transcripts sequenced in log2 of unique molecular identifier (UMI) counts +1.

To gain more insight into the position of the RUNX1-ETO-responsive cell population within the differentiation trajectory, we performed a pseudo-time (nearest neighbor) analysis ([Figure 7](#fig7){ref-type="fig"}). Uninduced cells showed a clear distribution of the different populations, with the eosinophil progenitor (orange), the myeloid (blue), and the erythroid progenitor lineages branching off ([Figure 7](#fig7){ref-type="fig"}A, left panel). Induction of RUNX1-ETO distorted this differentiation trajectory ([Figure 7](#fig7){ref-type="fig"}A, right panel); although the erythroid branch was unaffected, all other arms were disorganized, with cells from different clusters scattered over the trajectory. Our results are consistent with RUNX1-ETO halting differentiation, with cells forming a continuum of mixed differentiation stages rather than a trajectory, which would be in agreement with a blocked cell cycle and inability to properly execute lineage fate decisions=. The same scenario could be seen when the expression of specific genes in the different cell populations was projected on the trajectory ([Figure 7](#fig7){ref-type="fig"}B). The expression of genes such as *GATA2* and *SPI1* (PU.1) was scattered all over the trajectory after induction ([Figure 7](#fig7){ref-type="fig"}B), and their expression was downregulated in eosinophil progenitor (orange) and 5-Dox-enriched (green) populations ([Figure 7](#fig7){ref-type="fig"}B; [Figure S5](#mmc1){ref-type="supplementary-material"}). However, the analysis of *SPI1* (PU.1) expression in monocytes (purple) showed a different picture ([Figure 7](#fig7){ref-type="fig"}B; [Figure S5](#mmc1){ref-type="supplementary-material"}), because *SPI1* appeared to be less perturbed by RUNX1-ETO induction in this population, suggesting that cells that have passed a certain differentiation state become less sensitive to perturbation. This finding could be explained by activation of additional enhancers that do not depend on prior expression of RUNX1 ([@bib29]). In contrast, *SOX4* upregulation was confined to the eosinophil progenitor and the 5-Dox-induced cell population ([Figure S5](#mmc1){ref-type="supplementary-material"}).Figure 7RUNX1-ETO Induction Distorts the Myeloid, but Not the Erythroid, Differentiation Trajectory and Dysregulates Genes Involved in Stem/Progenitor Development(A) Trajectory analysis using the Monocle algorithm of the sorted cell populations plotted according to each cell cluster.(B) Expression of individual marker genes projected on the trajectories, plotted according to each cell cluster in (A). Color intensity represents number of transcripts sequenced in log2 of UMI counts +1.

Altogether, our results are consistent with the idea that RUNX1-ETO reprograms an early myeloid cell population, leading to the dysregulation of genes involved in stem/progenitor cell development, followed byarrested differentiation and cellular growth.

Discussion {#sec3}
==========

RUNX1-ETO Induction at Balanced Levels in Human Progenitor Cells Induces Quiescence and Promotes Their Survival {#sec3.1}
---------------------------------------------------------------------------------------------------------------

The t(8;21) translocation can be detected *in utero* and *RUNX1-ETO*-expressing clones can be found in post-natal blood samples, suggesting that cells that acquire the mutation might form a pre-leukemic clonal reservoir ([@bib67]). Our laboratories have established a protocol for the generation of CD34+RUNX1C+ definitive hematopoietic progenitors arising from *HOXA+* hemogenic vasculature that resemble cells generated during human intra-embryonic hematopoiesis within the AGM region ([@bib41]). These progenitors present transcriptional profiles, cell surface receptors, and signaling molecules similar to those of cells sorted from human AGM. The work presented here demonstrates that such cells also display an accessible chromatin landscape resembling the HSC/MPP pattern found in adult hematopoietic cells.

In agreement with previous experiments in murine ESCs ([@bib52]), *RUNX1-ETO* expression at high levels in differentiating human ESCs abrogated blood formation, and here we show that it perturbs vasculogenesis, similar to what has been shown in transgenic mice ([@bib68]). Expression of *RUNX1-ETO* before the EHT, even at an equivalent level to that of endogenous *RUNX1*, caused substantial disorganization of vascular structures and formation of morphologically abnormal hematopoietic progenitors. However, induction of the same level of RUNX1-ETO after the EHT allowed the formation of progenitor cells but promoted the accumulation of cell populations expressing markers of immature blood progenitors with a CD34+CD38−CD90+ phenotype. This CD34+CD38−CD90+CD45+RUNX1+ signature in our *RUNX1-ETO*-expressing progenitors is shared with an embryonic population of cells containing the first few definitive human HSCs ([@bib21]).

Balanced levels of RUNX1-ETO expression (1) do not block blood formation; (2) confer survival, but not proliferation, to a subset of progenitors; (3) do not cause apoptosis (data not shown); and (4) maintain cells in a quiescent stage. Moreover, the latent colony-forming activity of progenitors that had been previously rendered quiescent by RUNX1-ETO induction re-emerges upon removal of Dox from the methylcellulose CFU assay. These cells even exhibit a higher yield of colonies when compared with their uninduced counterparts, suggesting that cells with high replating activity accumulate in induced cultures and that the blocked differentiation state is reversible, even after extended *RUNX1-ETO* expression. This result is consistent with prior replating assays of *RUNX1-ETO*-expressing mouse bone marrow cells, which showed an increase of self-renewal, but not proliferation ([@bib53]). Our observations are also consistent with the idea of the existence of a reservoir of cells harboring the t(8;21) translocation in a quiescent pre-leukemic state, as reported by the presence of a small population of HSCs harboring the translocation in t(8;21) patients in remission ([@bib59]). In contrast, studies using retroviral transduction of human CD34+ cord blood hematopoietic cells to constitutively express *RUNX1-ETO* reported enhanced *in vitro* proliferation of these cells, while maintaining self-renewal and differentiation capacity ([@bib38], [@bib39]). These discrepancies might be explained by differences in the expression levels of *RUNX1-ETO* used and/or by selection of specific clones of cells that were outgrowing in culture ([@bib38], [@bib39]), indicating that the growth arrest can be surpassed. A dual role of RUNX1-ETO in blocking differentiation and arresting cell growth has been previously described ([@bib10]), although those authors observed that RUNX1-ETO-dependent growth arrest resulted in apoptosis. Those studies were conducted in a cell line (U937) representing a different type of AML, and probably carrying additional oncogenic mutations, suggesting that RUNX1-ETO cannot reprogram one leukemic cell type into another. This observation is consistent with previous work from our lab that showed that each leukemogenic mutation directs hematopoietic precursors through a different developmental path ([@bib1]).

RUNX1-ETO Induction Causes Extensive Global Chromatin Reorganization and Shuts Down the RUNX1-Directed Gene Expression Program {#sec3.2}
------------------------------------------------------------------------------------------------------------------------------

We found that the pattern of up- and downregulated RUNX1-ETO target genes is tightly correlated to changes observed in t(8;21) patient cells. Differential gene expression analyses upon induction of RUNX1-ETO showed downregulation of myelopoiesis, cell-cycle, and DNA repair genes. This finding is consistent with the expression of surface markers characteristic of immature cells in RUNX1-ETO-induced progenitors and the lack of proliferation of such cells. Interestingly, RUNX1-ETO induction caused an upregulation of genes from multiple signaling pathways, such as the MAPK pathway. General signaling pathway activation could occur as a survival response from the cells trying to compensate for the RUNX1-ETO-mediated block on the cell cycle. This hypothesis is supported by data from established t(8;21) AML cells that show that high *CDK6* and *CCND1/2* expression levels depend on the AP-1 transcription factor family, which mediates MAPK signaling and whose expression, in turn, depends on the presence of RUNX1-ETO ([@bib34]). Moreover, AP-1 is a critical factor for the establishment of t(8;21) AML in xenotransplantation experiments ([@bib1]). To develop overt disease, RUNX1-ETO cooperates with mutated growth factor receptors, such as KIT or FLT3 ([@bib56], [@bib66]), indicating that such mutations may act upon an already partially activated signaling landscape.

Changes in gene expression after induction of RUNX1-ETO were mediated by rapid reorganization of the chromatin landscape, leading to loss of accessibility of thousands of sites enriched in RUNX motifs and bound by RUNX1, although *RUNX1* expression per se was not affected. Concomitantly, H3K27ac was reduced, demonstrating that binding of RUNX1-ETO directly interferes with that of RUNX1. It has been shown that t(8;21) cells depend on the presence of a normal *RUNX1* allele, which is required to balance the detrimental effects of *RUNX1-ETO* expression by upregulating critical mitotic checkpoint genes ([@bib2], [@bib30]). It is therefore possible that restoring the growth of RUNX1-ETO-induced cells requires the re-establishment of at least part of the RUNX1-mediated gene expression program. This is likely to include the expression of *SPI1* (PU.1) ([@bib20]) or *CEBPA*, as well as genes that override the RUNX1-ETO-mediated cell-cycle block.

RUNX1-ETO Expression Blocks Myeloid Differentiation by Rapidly Downregulating *SPI1* and *CEBPA* Expression in Early Myeloid Cells {#sec3.3}
----------------------------------------------------------------------------------------------------------------------------------

Reprogramming of one cell fate into another requires a complete reorganization of the epigenome and is facilitated by reprogramming cells within a similar developmental pathway ([@bib17]), but it can also be enforced upon cells from different pathways by overexpression of complementary transcription factors ([@bib63]). One of the most important and unanswered questions in AML research is the understanding of the nature of the target cells that are susceptible to an oncogenic hit. This notion is exemplified by our finding that RUNX1C− and RUNX1C+ cells significantly differ in their response to the expression of the fusion protein. Our scRNA-seq data clearly demonstrate that only early multipotent myeloid precursors respond to RUNX1-ETO induction with a block in differentiation and growth arrest. We do not know where these cells exist in human embryos, only that they suffer strong downregulation of the myeloid master regulator PU.1, without which myelopoiesis is strongly perturbed ([@bib35], [@bib57]), providing a molecular explanation for the RUNX1-ETO-mediated differentiation block. Expression of *RUNX1-ETO* also leads to an upregulation of *SOX4* in the 5-Dox-enriched cell cluster, which is consistent with the downregulation of *CEBPA*. *SOX4* expression is required for self-renewal of HSCs, as well as leukemic stem cells (LSCs), and its expression has been shown to be upregulated in HSCs from *CEBPA* null mice and in patients with abnormal C/EBPα function ([@bib71]) and thus myelopoiesis.

In summary, we have shown that we can use the differentiation of human ESCs into definitive hematopoietic progenitor cells to gain insight into the earliest events of the reprogramming of the myeloid gene regulatory network by RUNX1-ETO and its interplay with RUNX1 in a human embryonic setting. Our future experiments are aimed at further understanding the nature of the growth stimulus required to overcome RUNX1-ETO-mediated growth arrest.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-HA tag (Abcam)SigmaCat\# H6908; RRID: [AB_260070](nif-antibody:AB_260070){#interref135}Anti-Histone H3 (Rabbit polyclonal)AbcamCat\# ab1791; RRID: [AB_302613](nif-antibody:AB_302613){#interref140}Anti-Histone H3K27acAbcamCat\# ab4729; RRID: [AB_2118291](nif-antibody:AB_2118291){#interref145}Anti-Histone H3K4me3MerkCat\# 07-473; RRID: [AB_1977252](nif-antibody:AB_1977252){#interref150}Anti-human AML1 (Rabbit Polyclonal)Cell Signaling TechnologyCat\# 4334; RRID: [AB_2184099](nif-antibody:AB_2184099){#interref155}Anti-LDB1AbcamCat\# ab96799; RRID: [AB_10679400](nif-antibody:AB_10679400){#interref160}Anti-LMO2R&D SystemsCat\# AF2726; RRID: [AB_2249968](nif-antibody:AB_2249968){#interref165}Anti-RUNX1AbcamCat\# ab23980; RRID: [AB_2184205](nif-antibody:AB_2184205){#interref170}APC anti-human CD38BD PharMingenCat\# 555462; RRID: [AB_398599](nif-antibody:AB_398599){#interref175}APC anti-human CD90BD PharMingenCat\# 559869; RRID: [AB_398677](nif-antibody:AB_398677){#interref180}BV-421 anti-human CD326 (EpCam)BioLegendCat\# 324220; RRID: [AB_2563847](nif-antibody:AB_2563847){#interref185}BV-421 anti-human CD34BioLegendCat\# 343609; RRID: [AB_11147951](nif-antibody:AB_11147951){#interref190}BV-421 anti-human CD45BioLegendCat\# 304032; RRID: [AB_2561357](nif-antibody:AB_2561357){#interref195}BV-421 anti-human CD90BioLegendCat\# 328121; RRID: [AB_10933261](nif-antibody:AB_10933261){#interref200}DyLight® 650-conjugated anti-HA tag \[16B12\]AbcamCat\# ab117515; RRID: [AB_10999718](nif-antibody:AB_10999718){#interref205}FITC-conjugated BrdU and IgGBD PharMingenCat\# 556028; RRID: [AB_396304](nif-antibody:AB_396304){#interref210}PE anti-human CD9BD PharMingenCat\# 555372; RRID: [AB_395774](nif-antibody:AB_395774){#interref215}PeCy7 anti-human CD16BioLegendCat\# 302015; RRID: [AB_314215](nif-antibody:AB_314215){#interref220}PeCy7 anti-human CD34BioLegendCat\# 343516; RRID: [AB_1877251](nif-antibody:AB_1877251){#interref225}**Bacterial and Virus Strains**One Shot™ TOP10 Chemically Competent *E. Coli*Thermo Fisher ScientificCat\# C404010**Chemicals, Peptides, and Recombinant Proteins**2-MercaptoethanolThermo Fisher ScientificCat\# 21985-023a- Monothioglycerol (MTG)MerckCat\# M6145Accutase solutionMerkCat\# A6964Activin A (ACT)R&D SystemsCat\# 338-ACAlbumin from rice endospermScienCell Research LabsCat\# OsSAAMPure magnetic beadsBeckman CoulterCat\# A63881Ascorbic acid 2-phosphate (AA2P)MerckCat\# A8960Bone morphogenetic protein 4 (BMP4)R&D SystemsCat\# 314-BPBovostar acid-stripped Bovine Serum Albumin (BSA)BovogenCat\# BSAS 0.1BrdUSigmaCat\# B5002CHIR99021Tocris BiosciencesCat\# 4423Collagenase Type 4WorthingtonCat\# CLS-4DigitoninPromegaCat\# G9441Dimethyl sulfoxide Hybri-MaxTM (DMSO)MerkCat\# D2650DMEM Nutrient Mixture F- 12 1x + L-glutamine Na bicarbonate (DMEM/F12)Thermo Fisher ScientificCat\# 11320-033Erythropoietin (EPO)PeproTechCat\# 100-64Fibroblast Growth Factor (FGF2)PeproTechCat\# 100-18BFixation/Permeabilization solutionBD PharMingenCat\# 554722FMS-like tyrosine kinase 3 receptor (FLT3) ligandPeproTechCat\# 300-19GlutaMAXI100xThermo Fisher ScientificCat\# 35050-061Ham's F12Thermo Fisher ScientificCat\# 11765-062Human low-density lipoproteins (hLDL)Stem Cell TechnologiesCat\# 02698Insulin-like growth factor 2 (IGF2)PeproTechCat\# 100-12Insulin-Transferrin-Selenium-E (ITS-E)In VitriaCat\# 777ITS092Interleukin 3 (IL-3)PeproTechCat\# 200-03Interleukin 6 (IL-6)PeproTechCat\# 200-06Iscove's Modified Dulbecco's Media (IMDM) with no phenol redThemo Fisher ScientificCat\# 21056-023KnockOut Serum Replacer (KO-SR)Thermo Fisher ScientificCat\# 10828028L-Ascorbic acidMerckCat\# A4403Linoleic acidMerckCat\# L2376Linolenic acidMerckCat\# L1376Matrigel Growth Factor Reduced phenol red-free*In Vitro* TechnologiesCat\# FAL356231Methanol-free FormaldehydeThermo Fisher ScientificCat\# 28906MethoCult™ H4100Stem Cell TechnologiesCat\# 01400NEBNext High-Fidelity 2x PCR Master MixNew England BiolabsCat\# M0541NextSeq® 500/550 High Output 150 cycle sequencing kit v2IlluminaCat\# FC-404-2002NextSeq® 500/550 High Output 75 cycle sequencing kit v2IlluminaCat\# FC-404-2005Non-essential amino acids (NEAA) 100XThermo Fisher ScientificCat\# 11140-050Penicillin/Streptomycin (Pen/Strep)Thermo Fisher ScientificCat\# 15140122Perm/Wash bufferBD PharMingenCat\# 554723Polyvinyl alcohol (PVA)MerckCat\# P8136Protein Free Hybridoma Medium II (PFHMII)Thermo Fisher ScientificCat\# 12040077SB431542Sapphire BioscienceCat\# 13031Soybean Oil (lecithin)MerckCat\# S7381Stem cell factor (SCF)PeproTechCat\# 300-07SuperScript II Reverse TranscriptaseThermo Fisher ScientificCat\# 18064022SyntheCholMerckCat\# S5442Thrombopoietin (TPO)PeproTechCat\# 300-18TrypLE™ Select EnzymeThermo Fisher ScientificCat\# 12563011Vascular endothelial growth factor (VEGF)PeproTechCat\# 100-20Vybrant DyeCycle Violet StainThermo Fisher ScientificCat\# V35003**Critical Commercial Assays**Bioline Isolate II RNA Mini KitBiolineCat\# BIO-52072CD34 UltraPure human MicroBeads KitMiltenyi BiotecCat\# 130-100-453Chromium Single Cell 3′ Library and Gel Bead Kit v210X GenomicsCat\# PN-120237High Sensitivity DNA ChipAgilent TechnologiesCat\# 5067-4626KAPA Hyper Prep KitRocheCat\# KR0961KAPA Library Quantification Kit Illumina Sequencing PlatformsRocheCat\# KR0405MACS Starting KitMiltenyi BiotecCat\# 130-091-632MinElute Reaction Cleanup KitQIAGENCat\# 28204Nextera DNA Library Prep KitIlluminaCat\# FC-121-1030Pierce BCA Protein Assay KitThermo Fisher ScientificCat\# 23225SuperSignal PICO reagent mixThermo Fisher ScientificCat\# 34579Tetro cDNA synthesis kitBiolineCat\# BIO-65042TruSeq® Stranded mRNA Library PrepIlluminaCat\# 20020594Universal Magnetic Co-IP KitActive MotifCat\# 54002**Deposited Data**Bulk RNA-seq dataThis studyGEO: [GSE137673](ncbi-geo:GSE137673){#interref230}ChIP-seq dataThis studyGEO: [GSE137673](ncbi-geo:GSE137673){#interref235}ATAC-seq dataThis studyGEO: [GSE137673](ncbi-geo:GSE137673){#interref240}scRNA-seq dataThis studyGEO: [GSE137673](ncbi-geo:GSE137673){#interref245}**Experimental Models: Cell Lines**SOX17^mCHERRY/w^RUNX1C^GFP/w^ hESC H9 line[@bib41]N/AInducible RUNX1-ETO SOX17^mCHERRY/w^RUNX1C^GFP/w^ hESC H9 lineThis paperN/A**Oligonucleotides**Oligonucleotide sequences, see [Table S1](#mmc1){ref-type="supplementary-material"}This paperN/A*GAPDH* (TaqMan assay)Thermo Fisher ScientificRRID: Hs99999905_m1*GATA1* (TaqMan assay)Thermo Fisher ScientificRRID: HS00231112_m1*GFI1* (TaqMan assay)Thermo Fisher ScientificRRID: Hs00382207_m1*GFI1B* (TaqMan assay)Thermo Fisher ScientificRRID: Hs01062469_m1*SPI1 (PU.1)* (TaqMan assay)Thermo Fisher ScientificRRID: HS00231368_m1*RUNX1 COMMON* (TaqMan assay)Thermo Fisher ScientificRRID: HS00231079_m1*RUNX1C* (TaqMan assay)Thermo Fisher ScientificRRID: Hs01021967_m1*RUNX1T1* (TaqMan assay)Thermo Fisher ScientificRRID: Hs00231702_m1**Recombinant DNA**pSIEW-RUNX1-ETO[@bib7]N/ApTREG-CAGGS-Tet3G-AAVS1[@bib49]N/A**Software and Algorithms**Trimmomatic v0.32[@bib6]<http://www.usadellab.org/cms/?page=trimmomatic>Bowtie2 v2.2.6[@bib28]<http://bowtie-bio.sourceforge.net/index.shtml>MACS2 v2.1.1[@bib70]<https://github.com/taoliu/MACS>Picard v2.10.5<http://broadinstitute.github.io/picard>N/AHomer v4.9.1[@bib18]<http://homer.ucsd.edu/homer/>R v3.5.1<https://www.R-project.org/>N/AJava TreeView v1.1[@bib55]<http://jtreeview.sourceforge.net/>deepTools v3.2.0[@bib51]<https://github.com/deeptools/deepTools>Hisat2 v2.1.0[@bib24]<https://daehwankimlab.github.io/hisat2/>Stringtie v1.3.3[@bib45]<https://ccb.jhu.edu/software/stringtie/>Limma v3.26.9[@bib54]<https://bioconductor.org/packages/release/bioc/html/limma.html>Cytoscape v3.6.1[@bib58]<https://cytoscape.org/>ClueGO v2.5.0[@bib4]<http://apps.cytoscape.org/apps/cluego>dynamicTreeCut v1.63[@bib27]<https://cran.r-project.org/web/packages/dynamicTreeCut/index.html>GSEA v2.2.4[@bib61]<https://www.gsea-msigdb.org/gsea/index.jsp>CellRanger v2.1.1<https://www.10xgenomics.com/><https://support.10xgenomics.com/single-cell-gene-expression/software/downloads/latest>Seurat v2.3.4[@bib11]<https://satijalab.org/seurat/>Monocle v2.10.1[@bib50], [@bib65]<http://cole-trapnell-lab.github.io/monocle-release/>**Other**Low attachment 96-well plates (Sterile)CostarCat\# COR3788Ultra-low attachment 24-well plates*In Vitro* ASCat\# NUN1445304-20% gradient polyacrylamide gelBioradCat\# 456-8093AML patient RNA-seq data[@bib1]GEO: [GSE108316](ncbi-geo:GSE108316){#interref250}Hematopoietic progenitor RNA-seq data[@bib14]GEO: [GSE74912](ncbi-geo:GSE74912){#interref255}

Resource Availability {#sec4.2}
---------------------

### Lead contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Constanze Bonifer (<c.bonifer@bham.ac.uk>).

### Materials availability {#sec4.2.2}

The targeting plasmid and the inducible RUNX1-ETO cell lines generated in this study are available from the Lead Contact.

### Data and code availability {#sec4.2.3}

All high throughput data (bulk RNA-seq, ChIP-seq, ATAC-sec and scRNA-seq data) generated in this study are available at NCBI under the accession number GEO: [GSE137673](ncbi-geo:GSE137673){#intref0110}.

The published article includes AML patient RNA-seq data ([@bib1]) with GEO: [GSE108316](ncbi-geo:GSE108316){#intref0115} and hematopoietic progenitor RNA-seq data ([@bib14]) with GEO: [GSE74912](ncbi-geo:GSE74912){#intref0120}, analyzed during this study.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Generation and validation of targeted inducible RUNX1-ETO human ESC lines {#sec4.3.1}

The dual reporter SOX17^mCHERRY/w^RUNX1C^GFP/w^ human ESC H9 line was previously generated by us ([@bib41]), by targeting mCHERRY into exon 1 of one allele of SOX17 and GFP into exon 1 of one allele of RUNX1. RUNX1-ETO cDNA was amplified from the pSIEW-RUNX1-ETO vector with primers including a HA tag sequence following the Kozak sequence containing the start codon and restriction endonuclease sites SalI (5′) and MluI (3′) for subsequent cloning into the multiple cloning site of the pTREG-CAGGS-Tet3G-AAVS1 knockin plasmid. The primers used for cloning are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. The pSIEW-RUNX1-ETO and the pTREG-CAGGS-Tet3G-AAVS1 vectors were gifts from Olaf Heidenreich (Newcastle, UK) ([@bib7]) and Su-Chun Zhang (Wisconsin, US) ([@bib49]), respectively. RUNX1-ETO-AAVS1 targeting vectors comprised a 804-bp 5′ homology arm, a tetracycline-inducible promoter (TRE3G-CMV) driving expression of HA-RUNX1-ETO cDNA sequence, Puromycin N-acetyltransferase resistance cassette with gene expression to be driven by endogenous promoter after genomic insertion, a CAG promoter driving expression of a modified Tet3G reverse tetracycline-controlled transactivator (rtTA) and a 837-bp 3′ homology arm. Vectors were electroporated with a pair of AAVS1 Transcription Activator-Like Effector Nucleases (TALENs) into SOX17^mCHERRY/w^RUNX1C^GFP/w^ human ESC H9 cells, which were then selected for Puromycin-resistant colony growth. Single cell sorted clones were screened for transgene insertion by PCR using primers designed to amplify the boundaries of the genomic insertion. Homozygous or heterozygous targeting of the AAVS1 locus was identified with a pair of primers designed to cover both locus sides, resulting in fragment amplification only in presence of a wild-type allele. The primers used for screening targeted clones are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. Genomic integrity in all clones was confirmed using the Illumina HumanCytoSNP-12 v2.1 array.

### Maintenance of human ESC cultures {#sec4.3.2}

Culture and enzymatic passaging of human ESC lines was conducted as previously reported ([@bib40]). Briefly, human ESCs were routinely co-cultured with mitotically inactivated primary mouse embryonic fibroblasts in a defined serum-free media in a humidified incubator at 37°C with 5% CO2 and low (5%) O2 conditions. The filter-sterilized media consisted of DMEM/F12 supplemented with 20% KO-SR, 1x NEAA, 200 mM GlutaMAXTMI, 55 mM 2-Mercaptoethanol and 10 ng/ml FGF2. All cell centrifugations were done at 300 x g for 3 min at 4°C. Passaging of human ESC cultures was performed using TrypLE™ Select Enzyme. Cells were cryopreserved in 10% DMSO and CJ2 solution, consisting of 20x Choline Chloride (382 mg/ml in dH~2~O), 0.01 mM CaCl~2~.2H~2~O, 2.68 mM KCl, 1.47 mM KH~2~PO~4~, 6.54 mM K~2~HPO~4~.3H~2~O, 0.5 mM MgCl~2~.6H~2~O and 5.5 mM D-glucose in dH~2~O.

### *In vitro* hematopoietic differentiation of human ESC {#sec4.3.3}

Hematopoietic differentiation of human ESCs was performed with a modified protocol of the spin Embryo Body (EB) method in serum-free STAPEL medium ([@bib40]) supplemented with recombinant human protein components, as reported ([@bib41]). STAPEL medium consisted of a mixture of 50% IMDM, 50% Ham's F12 and 0.05% PVA, supplemented with: 0.5% albumin (1:1 mix of albumin from rice endosperm and Bovostar acid-stripped BSA), 1x PFHMII, 0.03% MTG, 2.2 μg/ml SyntheChol, 100 ng/ml Linolenic and Linoleic acids, 0.005 mg/ml Soybean Oil, 2 mM GlutaMAXI, 50 μg/ml AA2P, 50 μg/ml L-Ascorbic acid and 1x ITS-E. To set up the differentiation (day 0), human ESCs were harvested from a confluent (95%--98%) T75 flask without feeders using Accutase solution and mixed into 50 mL of STAPEL media supplemented with cytokines (herein referred as STAGE1): 20 ng/ml BMP4, 25 ng/ml VEGF, 25 ng/ml SCF, 7.5 ng/ml ACT, 10 ng/ml FGF2 and 0.5 μM CHIR99021. All human cytokines used for hematopoietic differentiation were recombinant. Following cell resuspension in STAGE1 media, 80 μL were distributed into the each of the 60 inner wells of 10 low attachment 96-well plates, pre-filled with 70 μL sterile ddH~2~O in the outer wells. Cells were aggregated into EBs (60 EBs/plate) at the bottom of the wells by centrifugation. Plates were incubated at 37°C with 5% CO~2~ and high (air levels) O~2~ conditions. Approximately 4--6 h before the 48-hour time point from set up (day 1.6-1.7), 20 μL of STAPEL supplemented with 3.5 μM SB431542 and 3 μM CHIR99021 were added to each well. After day 4, STAGE 1 media was removed and 100 μL of STAGE2 STAPEL were added to each well. STAGE2 cytokines consisted of 5 ng/ml BMP4, 50 ng/ml VEGF, 50 ng/ml SCF, 10 ng/ml IGF2 and 10 ng/ml FGF2. At day 8, 20--30 EBs/well were transferred onto 6-well adherent plates pre-coated with Matrigel solution (IMDM with 1x Pen/Strep and 1:200 Corning® Matrigel® Growth Factor Reduced phenol red-free). Adherent cultures after d8 were fed with STAGE3 STAPEL supplemented with 20 ng/ml BMP4, 100 ng/ml SCF, 100 ng/ml FLT3, 50 ng/ml VEGF, 50 ng/ml TPO, 25 ng/ml IL-3, 25 ng/ml IL-6, 20 ng/ml IGF2, 10 ng/ml FGF2 and 1x Pen/Strep. Plates were toped up with media every 2--3 days and half-media changes were performed when the media capacity of the plate was reached. After progenitor formation (∼d14), cultures were supplemented with a '5-factor' cytokine mix including 100 ng/ml SCF, 100 ng/ml FLT3 ligand, 50 ng/ml TPO, 25 ng/ml IL3 and 25 ng/ml IL-6. During the 7-day Dox treatment, Dox was refreshed at the half-media changes (every 2--3 days). For analysis, EBs were harvested at different time points and dissociated into single-cell suspensions using TryPLE select for non-adherent EBs (d7) and Collagenase Type 4 for adherent EB cultures and passed through 23- and 25-gauge needles and a 40 μm filter ([@bib40]).

Method Details {#sec4.4}
--------------

### Flow cytometric analysis {#sec4.4.1}

Flow cytometric analysis was performed using BD Fortessa analyzer using antibodies against surface antigens detailed in the [Key Resources Table](#sec4.1){ref-type="sec"}. For intracellular flow cytometric analysis, cell pellets were fixed with Fixation/Permeabilization solution on ice for 30 min. Cell suspensions were washed with 1x Perm/Wash buffer (BD PharMingen cat\# 554723) and HA-RUNX1-ETO was detected using a primary conjugated antibody against the HA-tag (Anti-HA tag \[16B12\] DyLight® 650-conjugated, Abcam cat\# ab117515).

### Cell sorting {#sec4.4.2}

Fluorescence-activated cell sorting (FACS) was done in a FACS Aria cell sorter. Antibodies against CD9 and EpCam were used for sorting undifferentiated human ESCs and against CD34, CD45 and CD90 for sorting hematopoietic progenitors ([Key Resources Table](#sec4.1){ref-type="sec"}). Magnetic-activated cell sorting (MACS) of the CD34^high^ hematopoietic cell population was performed using CD34 UltraPure human MicroBeads Kit and a Mini (MS) & Midi (ML) MACS Starting Kit, as in the manufacturer's protocol.

### Intracellular immunostaining {#sec4.4.3}

Adherent cells on 48-well plates were fixed and permeabilized by 15 min incubation at room temperature with 4% Paraformaldehyde and 0.5% Triton solution. Non-specific binding of proteins to the antibody was blocked with 10% FCS Perm/Wash buffer. HA-RUNX1-ETO was detected using an Anti-HA-tag primary conjugated antibody and nuclei were stained with DAPI. Cells were subsequently analyzed by epifluorescence imaging.

### Imaging {#sec4.4.4}

Epifluorescence images of the *in vitro* hematopoietic cultures and immunostainings were taken using the 10x and 20x objectives of a Zeiss AxioObserver Z1 microscope and a Zeiss AxioCam monochrome camera and were processed with the Zen Blue software. Confocal images of the *in vitro* hematopoietic cultures were taken with a Zeiss LSM780 microscope using a 10x objective and processed with Zen Black software. All images were exported as separate layers in JPEG format and assembled in Adobe Photoshop when required. Brightness and contrast adjustments were applied equally to all images.

### Colony-forming assays {#sec4.4.5}

Colony-forming-unit (CFU) assays were performed as reported ([@bib41]) with some modifications. Briefly, 3--5 × 10^3^ cells were cultured in 1% methylcellulose, supplemented with the '5-factor' cytokine mix (described in hematopoietic differentiation section) plus 10 μg/ml hLDL and 5 U/ml EPO. For the preparation of 1% methylcellulose, 40 mL serum-free 2.6% MethoCult™ H4100 was mixed with an equal volume of 2x STAPEL-P medium (STAPEL medium made with IMDM containing 2x supplements and without PFHMII) plus 20 mL of 1x STAPEL medium to give a final volume of 100 ml. Cells were cultured either with or without Dox and each condition was set up in triplicates in ultra-low attachment 24-well plates. Plates were scored for hematopoietic CFUs after 7 to 10 days.

### Replating assays {#sec4.4.6}

Replating assays were conducted on non-adherent hematopoietic progenitors plated at a known concentration on Matrigel-coated 6-well plates. Cells were harvested, counted and replated weekly. Live and death cells were determined using a FL Countess-II Automated Cell Counter (Thermo Fisher Scientific) after Trypan-Blue staining.

### Cell cycle analysis {#sec4.4.7}

Cells in culture were incubated for 3 h with 25 μM BrdU and non-adherent progenitor cells were fixed in 75% ethanol. Suspensions of fixed cells were pelleted and re-hydrated with PBS for 20 min and double stranded DNA was subsequently denatured by 20-minute incubation with 200 μL 2N HCl. Cells were washed twice with PBS and twice with blocking buffer (5% FBS, 0.1% NaN~3~, 0.1% TritonC100 in PBS). Samples were subjected to RNaseA treatment (100 μg/ml) in PBS for 30 min at 37°C and both IgG control and BrdU stainings were performed using FITC-conjugated antibodies at room temperature for 50 min. Cells were washed with PBS and incubated for 30 min with 1 μM Vybrant DyeCycle Violet Stain in PBS prior to flow cytometric analysis.

### Western Blotting {#sec4.4.8}

Nuclear protein extracts were prepared from progenitor cells floating in culture using the Universal Magnetic Co-IP Kit and quantified using the Pierce BCA Protein Assay Kit, following the manufacturer's protocol. Protein samples were diluted to the same amount, denatured at 95°C for 10 min and run on a 4%--20% gradient polyacrylamide gel. Proteins in the gel were then transferred to a nitrocellulose membrane using the mixed protocol in a Transblot Turbo (BioRad). The membrane was blocked with 5% milk in Tris Buffered Saline Tween (TBST) prior to hybridization with primary antibody (anti-AML1, 1:1,000 diluted in 5% milk TBST) overnight at 4°C. The membrane was then washed with TBST and incubated with an anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:10,000 in 5% milk TBST) for 1h at room temperature. The membrane was then subjected to TBST washes and enhanced chemiluminescence was detected in a developer following incubation with SuperSignal PICO reagent mix. Nuclear loading control was performed using an anti-H3 antibody (1:10,000).

### Gene expression analysis {#sec4.4.9}

Total RNA was extracted using the Bioline Isolate II RNA Mini Kit according to the manufacturer's instructions. cDNA was reverse-transcribed using random hexamer priming and Tetro cDNA synthesis kit or using Oligo (dT)~18~ priming and SuperScript II Reverse Transcriptase, according to the manufacturer's guidelines. Gene expression was analyzed by quantitative real-time PCR analysis using Taqman reagents and probes or SYBR Green master mix and primers designed to amplify cDNA fragments. All probes and primers are listed in [Key Resources Table](#sec4.1){ref-type="sec"}. Analyses were performed in technical duplicates and GAPDH was used as the reference gene to normalize data.

### RNA-Seq library preparation {#sec4.4.10}

RNA-sequencing (seq) libraries were prepared using a TruSeq® Stranded mRNA Library Prep following the Low Sample (LS) workflow according to manufacturer's instructions. Libraries were subjected to a quality control using a High Sensitivity DNA chip on an Agilent Technologies 2100 Bioanalyser instrument and were quantified using the RT-qPCR-based method KAPA Library Quantification Kit for Illumina Sequencing Platforms, following the manufacturer's protocol. Libraries were run in a pool of twelve indexed libraries in a NextSeq (Illumina) machine using sequencing by synthesis chemistry and a NextSeq® 500/550 High Output 150 cycle sequencing kit v2, obtaining 75 bp paired-end reads.

### Assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) {#sec4.4.11}

Chromatin accessibility was evaluated by ATAC-seq using a modified protocol to as reported ([@bib9], [@bib14]). Briefly, 50,000 single-cell sorted hematopoietic progenitors were pelleted and snap-frozen upon resuspension in 5 μL sucrose freezing buffer, consisting of 60 mM KCl, 15 mM NaCl, 5 mM MgCl~2~, 10 mM Tris pH 7.4 and 1.5 M sucrose. Transposition reaction was performed for 30 min at 37°C upon addition of 45 μL of ATAC reaction mix, consisting of 25 μL Tagmentation DNA Buffer and 2.5 μL Tn5 Transposase enzyme (both from the Nextera DNA Library Prep Kit), 1 μL of 0.5% Digitonin and 16.5 μL water. DNA was purified using a MinElute Reaction Cleanup Kit and DNA fragments were subsequently amplified using Customized Nextera PCR Primer Adaptors and NEBNext High-Fidelity 2x PCR Master Mix. Optimal number of cycles, prior reaching saturation of the PCR in order to reduce GC and size bias, was determined by monitoring the reaction as previously described ([@bib9]). Adaptor dimers were cleaned up from the libraries using AMPure magnetic beads prior to validation. Libraries were evaluated using a High Sensitivity DNA chip on an Agilent Technologies 2100 Bioanalyser instrument and concentration was measured using a KAPA Library Quantification Kit. Libraries were also validated by RT-qPCR evaluation of the ratio of open (TBP promoter) to closed regions of DNA (chromosome 18) and active gene body (β-actin). Libraries were sequenced in a pool of twelve indexed libraries in a NextSeq (Illumina) machine and a NextSeq® 500/550 High Output 75 cycle sequencing kit v2, obtaining 75 bp single-end reads, at the Genomics Birmingham sequencing facility.

### Chromatin Immunoprecipitation with high-throughput sequencing (ChIP-Seq) {#sec4.4.12}

All ChIP experiments were performed after single crosslink with 1% methanol-free formaldehyde for 10 min, as reported ([@bib44]). RUNX1, RUNX1-ETO (HA tag), LMO2, and LDB1 ChIP experiments (0 and 5 ng/ml Dox samples) were performed on CD34+ magnetic sorted progenitors. H3K4me3, H3K27ac (0 and 5 ng/ml Dox samples) and RUNX1 and RUNX1-ETO (HA tag) (0, 5 and 10 ng/ml Dox samples) were performed on non-adherent mixed progenitors (\> 30% CD34+). Antibodies used are listed in [Key Resources Table](#sec4.1){ref-type="sec"}. ChIP libraries for Illumina sequencing were prepared using the KAPA Hyper Prep Kit, as detailed by the manufacturer. Quality control of the libraries was performed using a High Sensitivity DNA chip on an Agilent Technologies 2100 Bioanalyser instrument and libraries were quantified using a KAPA Library Quantification Kit. Libraries were sequenced in a pool of twelve indexed libraries in a NextSeq (Illumina) machine and a NextSeq® 500/550 High Output 75 cycle sequencing kit v2.

### Single Cell RNA-Seq (scRNA-Seq) {#sec4.4.13}

Non-adherent progenitors at day 22 of differentiation (untreated and upon 24-hour Dox treatment) were sorted for CD45+ CD34+ and RUNX1C+. Cells were re-suspended in 80 μL at a concentration of 100-1200 cells/μl for evaluation of cell viability prior to loading of 4000 single cells on a Chromium Single Cell Instrument (10X Genomics). Library generation for scRNA-seq was performed by the Genomics Birmingham Sequencing Facility using the Chromium Single Cell 3′ Library and Gel Bead Kit v2. Libraries were paired-end sequenced on an Illumina NextSeq machine using the cycle parameters recommended by 10X Genomics.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Statistical analysis {#sec4.5.1}

Experiments were analyzed using GraphPad Prism versions 5--7 (GraphPad Software Inc.) and Microsoft Excel (Microsoft corporation).

### Bulk RNA-Seq data analysis {#sec4.5.2}

Sequencing adaptors and low quality bases were trimmed from the raw RNA-Seq reads using Trimmomatic v0.32 ([@bib6]). The processed reads were then aligned to the human genome (version hg38) using Hisat2 v2.1.0 ([@bib24]) with default settings. Gene expression was measured as fragments per kilobase of transcript per million mapped reads (FPKM) values using with Stringtie v.1.3.3 ([@bib45]) with default settings. Gene models from the RefSeq database ([@bib43]) were used as the reference transcriptome. Only genes that were expressed with an FPKM \> 1 in at least one of the samples were retained for further analysis. The raw FPKM values were quantile normalized using the Limma package v3.26.9 ([@bib54]) in R v3.5.1. The normalized data were then log2-transformed, with a pseudocount of 1 being added to each of the FPKM values prior to transformation. Differential gene expression analysis was carried out using Limma. A gene was considered to be differentially expressed if it had a greater than 2-fold change between experimental conditions, and a Benjamini-Hochberg adjusted p value \< 0.05. Kyoto encyclopedia for genes and genomes (KEGG) pathway enrichment analysis was done using the ClueGO plugin v2.5.0 ([@bib4]) for Cytoscape v.3.61 ([@bib58]). This was done using a right-sided hypergeometric test, with Benjamini-Hochberg p value correction for multiple testing. A pathway was deemed to be significantly enriched if the adjusted p value was \< 0.05. Hierarchical clustering of RNA-Seq samples and replicates was done by first calculating the Pearson correlation value for each pair of samples. The resulting correlation matrix was then hierarchically clustered using complete linkage clustering of the Euclidean distances, and finally plotted as a heatmap in R. To carry out gene expression co-variance analysis, gene expression values were first transformed to Z-scores using the scale function in R. These were then hierarchically clustered using complete linkage of the Euclidean distances. Clusters corresponding to sets of genes with similar patterns of expression were then extracted from the dendrogram using the dynamicTreeCut package v1.63 ([@bib27]) in R using the hybrid method with a minimum cluster size of 25 genes. To compare the gene expression profile of the RUNX1-ETO induced cells to that of AML patients with the t(8;21) translocation, RNA-Seq data from t(8;21) patients and from healthy peripheral blood stem cells (PBSCs) from [@bib1] was downloaded from GEO using the accession GEO: [GSE108316](ncbi-geo:GSE108316){#interref260}. These data were aligned and processed as described above. The sets of genes that were up and downregulated in the RUNX1-ETO induced cells was then compared to the gene expression profiles of the t(8;21) AML cells and PBSCs using gene set enrichment analysis (GSEA) using the GSEA software ([@bib61]).

### ATAC-Seq data analysis {#sec4.5.3}

Single-end reads from ATAC-Seq experiments were processed to remove low-quality bases and sequencing adaptors using Trimmomatic. Reads were then aligned to the human genome (version hg38) using Bowtie2 v2.2.6 ([@bib28]) with the parameter--very-sensitive-local. Reads that aligned to the mitochondrial genome were removed from further analysis. Potential PCR duplicated reads were identified and removed from the alignments using Picard v2.10.5 (<http://broadinstitute.github.io/picard>). Open chromatin regions (peaks) were identified using MACS2 v2.1.1 ([@bib70]) using the settings--nomodel--nolambda -B--trackline. The resulting peaks were then filtered against the hg38 blacklist and simple repeat tracks from the UCSC table browser ([@bib23]) to remove any potential artifacts. Peaks were annotated to the nearest gene, and then further annotated as either a promoter of distal element using the annoatePeaks.pl function in the Homer software package v4.9.1 ([@bib18]). A peak was annotated as being within a gene promoter if it was within 1.5kb of a transcription start site (TSS) and as a distal element otherwise. ATAC peak unions were constructed by merging peaks that had summit positions within 400 bp of each other. In these cases, peaks were combined to a single peak with a new summit position defined as the mid-point between the summit positions of the original peaks. These average peak positions were used in all further downstream analysis. To identify regions of differential chromatin accessibility, a peak union was first created for each pair of samples being considered. The read density for these peaks was then retrieved directly from the bedGraph files produced by MACS2 using the annotatePeaks.pl function in Homer with the parameter -size 200. These tag counts were normalized as counts per million (CPM) in R, and further log2-transformed with a pseudocount of 1 added to each value prior to transformation. A peak was considered to be differentially accessible if the fold-difference of the normalized tag count was greater than 2 between experiments. Motif enrichment analysis was then carried out in these sets of peaks using the findMotifsGenome.pl function in Homer. To create read density plots, peaks were first ordered according to fold-difference. The read density in a 2kb window centered on the peak summits was then calculated using from the bedGraph files produced by Homer using the annotatePeaks.pl file in Homer, using the options -size 2000 -hist 10 -ghist. These were then plotted as heatmaps using java TreeView v1.1 ([@bib55]). ATAC-Seq data from hematopoietic cell type in various stages of differentiation were obtained from [@bib14] via GEO using the accession GEO: GSE74912. These data were aligned and processed as described above.

### ChIP-Seq data analysis {#sec4.5.4}

Reads from ChIP-Seq experiments were processed, aligned to the human genome and de-duplicated in the same way described above for the ATAC-Seq data. Peaks from ChIP-Seq experiments targeting the transcription factors RUNX1, RUNX1-ETO, LDB1 and LMO2 were identified using MACS2 with default settings. These peaks were then compared to the ATAC-Seq data, with only peaks that occurred within open chromatin regions being retained for further analysis. To identify differential binding of RUNX1 between the 0 and 5 Dox datasets, a union of RUNX1 peaks was first constructed by merging peaks that had summits within 100 bp of each other. The read density in these peaks was then retrieved using the annoatePeaks.pl function in Homer and normalized as counts per million in R. Peaks that had a fold-difference of at least 2 were considered to be differentially bound between experiments. RUNX1 and RUNX1-ETO target genes were identified by annotating each peak to its closest TSS using the annotatePeaks.pl function in Homer. Peaks corresponding to the histone modifications H3K27ac and H3K4me3 were called using MACS2 with default settings. These peaks were then filtered against the hg38 blacklist and simple repeat tracks from the UCSC table browser to remove any potential artifacts.

### Construction of average profiles {#sec4.5.5}

Average profiles for ATAC and ChIP-Seq data were constructed by first normalizing each of the alignment tracks as counts per million (CPM) using the bamCoverage function in deepTools v3.2.0 ([@bib51]). These were then plotted using the plotProfile function in deepTools.

### Single cell RNA-Seq data analysis {#sec4.5.6}

Illumina base call (BCL) files that were generated using the Chromium platform from 10x genomics were de-multiplexed and converted to the fastq format using the mkfastq function in CellRanger v2.1.1. These were then aligned to the human genome (version hg38) using the count function in CellRanger. Gene models from the RefSeq database were used as the reference transcriptome. Unique molecular identifier (UMI) counts were processed and normalized using the Seurat v2.3.4 package ([@bib11]) in R. Cells with less than 1500 detectable genes, or that had more than 10% of UMIs aligned to mitochondrial genes were removed from further analysis. Additionally, genes that were detected in less than 20 cells were also excluded from analysis. The cell cycle stage for each cell was inferred using the CellCycleScoring function in Seurat. The possible effects of cell cycle stage, as well as sequencing depth (as measured by the total number of UMIs) per cell were removed from the analysis by linear regression using the ScaleData function in Seurat. Clustering of cells was performed by first combining the datasets from the 0 and 5 dox treated cells into a single dataset using canonical correlation analysis (CCA). This combined dataset was then clustered using the t-distributed stochastic neighbor embedding (t-SNE) method. Cell clusters were identified using the FindClusters function in Seurat, using a resolution value of 0.4. Cell marker genes, corresponding to genes that are enriched on one cluster relative to others, were identified using the FindMarkers function. A gene was considered as a marker gene if it had a log fold-change value greater than 0.5 and could be detected in at least 50% of cells in that cluster. Differential gene expression analysis was also carried out for each cluster using the FindMarkers function, with genes with a log-fold-change greater than 0.25 and an FDR \< 0.05 being considered to be differentially expressed. Cell trajectory (pseudotime) analysis was carried out using Monocle v2.10.1 ([@bib50], [@bib65]). Normalized UMI counts from Seurat were first imported into Monocle using the importCDS function. Cells were then ordered along a pseudotime trajectory using the discriminative dimensionality reduction with trees (DDRTree) method using the complete set of cell marker genes identified by Seurat to order the cells.
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